Photo from wikipedia
Products containing the sedative/hypnotic zolpidem were subject to Drug Safety Communications (DSCs) in January and May 2013 describing the risk of next‐morning impairment and recommending lower starting doses particularly for… Click to show full abstract
Products containing the sedative/hypnotic zolpidem were subject to Drug Safety Communications (DSCs) in January and May 2013 describing the risk of next‐morning impairment and recommending lower starting doses particularly for women. This study aimed to assess whether zolpidem DSCs were associated with prescribing‐pattern changes between January 2011 and December 2013.
Keywords:
zolpidem;
drug safety;
changes prescribing;
safety communications
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Pharmacoepidemiology and Drug Safety
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!